IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i2p1448-d1034344.html
   My bibliography  Save this article

Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021

Author

Listed:
  • Chana Azzoug

    (“Pôle Personnes Âgées”, Hospital of Champmaillot, University Hospital, 21079 Dijon, France)

  • Gilles Nuémi

    (Medical Information Department, University Hospital, 21079 Dijon, France)

  • Didier Menu

    (“Mutualité Sociale Agricole” of Burgundy Franche Comté, 21000 Dijon, France)

  • Emmanuel De Maistre

    (Haemostasis Unit, University Hospital, 21079 Dijon, France)

  • Mathieu Boulin

    (Pharmacy Department, University Hospital, 21079 Dijon, France)

  • Alain Putot

    (Department of Internal Medicine and Infectious Diseases, Pays du Mont Blanc Hospital, 74700 Sallanches, France
    Physiopathologie et Épidémiologie Cérébro-Cardiovasculaires (PEC2), EA 7460, University of Burgundy, 21000 Dijon, France)

  • Patrick Manckoundia

    (“Pôle Personnes Âgées”, Hospital of Champmaillot, University Hospital, 21079 Dijon, France
    INSERM U-1093, Cognition, Action and Sensorimotor Plasticity, University of Burgundy, 21000 Dijon, France)

Abstract

Two main types of oral anticoagulants are available in France: vitamin K antagonists (VKA) and, more recently, direct oral anticoagulants (DOAC). The benefit–risk profile appears to be favorable for DOAC, which is as effective as VKA but safer (fewer cases of severe and cerebral bleeding). In a study in 2017, we observed that older adults did not seem to receive the same modalities of oral anticoagulants as younger individuals for various reasons. To assess anticoagulation prescribing practices over time, we repeated this cross-sectional study by comparing very old individuals taking DOAC to those taking VKA. Ambulatory individuals aged 80 years and older were included. They were affiliated with the Mutualité Sociale Agricole of Burgundy and were refunded for a medical prescription of oral anticoagulation in March 2021. The demographic characteristics, registered chronic diseases (RCD), number and types of prescribed drugs, and mortality of the DOAC group and the VKA group were compared. A total of 4275 subjects were included in the study: 67.44% (2883) received DOAC and 32.56% (1392) received VKA. The two groups were similar in age. In the DOAC group, there were more women (54.98% vs. 46.98%) ( p < 0.001), fewer RCD (91.47% vs. 93.68%) ( p = 0.014), and lower rates of venous thromboembolism (2.53% vs. 6.75%) ( p < 0.001), severe heart failure (56.50% vs. 68.03%) ( p < 0.001), and severe kidney diseases (1.38% vs. 3.59%) ( p < 0.001), but there were more subjects with Alzheimer’s disease (7.49% vs. 4.31%) ( p = 0.001). Individuals in the DOAC group had fewer prescriptions of furosemide (48.53% vs. 55.75%) ( p < 0.001) and fibrates (2.32% vs. 3.88%) ( p = 0.044). They also had more prescriptions of proton pump inhibitors (43.95% vs. 39.44%) ( p = 0.006) and antirheumatics (1.60% vs. 0.65%) ( p = 0.009) than those in the VKA group. There was no difference in mortality. This study revealed that prescribing practices for DOAC have changed over time.

Suggested Citation

  • Chana Azzoug & Gilles Nuémi & Didier Menu & Emmanuel De Maistre & Mathieu Boulin & Alain Putot & Patrick Manckoundia, 2023. "Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021," IJERPH, MDPI, vol. 20(2), pages 1-13, January.
    • Handle: RePEc:gam:jijerp:v:20:y:2023:i:2:p:1448-:d:1034344
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/2/1448/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/20/2/1448/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:2:p:1448-:d:1034344. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.